Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

[Immunogenicity and safety of a booster dose of inactivated polio vaccine].

Li XM, Zhang ZJ, Wang HH, Liu F, Zhang LW, Chu P, Xu Y, Zhang HR, Li J, Liu DL, Lu L.

Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Oct;47(10):905-9. Chinese.

PMID:
24378129
2.
3.

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.

Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.

Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21.

PMID:
24063976
4.
5.

Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.

Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.

Pediatr Infect Dis J. 2008 Apr;27(4):341-6. doi: 10.1097/INF.0b013e3181616180.

PMID:
18316985
7.

[Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].

Lu L, Li XM, Liu DL, Zhang HR, Zhang ZJ, Wang HH, Liu F, Ning ZQ, Zhang LW, Chu P, Xie YT, Xu Y, Li J, Pang XH, Deng Y.

Zhonghua Yu Fang Yi Xue Za Zhi. 2012 Jun;46(6):510-3. Chinese.

PMID:
22943896
8.

Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.

Resik S, Tejeda A, Fonseca M, Alemañi N, Diaz M, Martinez Y, Garcia G, Okayasu H, Burton A, Bakker WA, Verdijk P, Sutter RW.

Vaccine. 2014 Sep 22;32(42):5399-404. doi: 10.1016/j.vaccine.2014.07.109. Epub 2014 Aug 12.

PMID:
25131734
9.

Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.

Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, Sänger R, Jacquet JM, Schuerman L.

Pediatr Infect Dis J. 2005 Jan;24(1):70-7.

PMID:
15665713
10.
11.

Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Mar;16(3):321-30. doi: 10.1016/S1473-3099(15)00488-0. Epub 2015 Dec 21.

PMID:
26719058
12.

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.

Pietrzyk JJ, Wysocki J, Pejcz J, Galaj A, Majda-Stanislawska E, Käyhty H, Thierry-Carstensen B, Jensen AM.

Vaccine. 2008 Sep 26;26(41):5296-303. doi: 10.1016/j.vaccine.2008.07.033. Epub 2008 Aug 27.

PMID:
18675870
13.

Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.

Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):282-94.

PMID:
19323013
14.

Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants.

Lu L, Li X, Zhang H, Liu D, Zhang Z, Wang H, Liu F, Ning Z, Li J, Pang X.

Vaccine. 2015 Aug 26;33(36):4653-8. doi: 10.1016/j.vaccine.2014.08.091. Epub 2015 Feb 11.

PMID:
25681659
16.
17.
18.

Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.

Black S, Friedland LR, Schuind A, Howe B; GlaxoSmithKline DTaP-IPV Vaccine Study Group.

Vaccine. 2006 Aug 28;24(35-36):6163-71. Epub 2006 Apr 21.

PMID:
16759769
19.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
Items per page

Supplemental Content

Write to the Help Desk